In prostate cancer (PC) the androgen receptor (AR) binds predominantly to gene-distal sites and has been used by multiple groups to functionally annotate genetic risk loci based on overlaps with risk single nucleotide polymorphisms (SNPs) as measured in genome-wide association studies (GWAS), which in some cases are also predicted to affect AR binding [7, 8]. This evidence concerns the gene AR and prostate carcinoma.